Dear Mr. Maybarduk,

Thank you for your letter. We recognize there is a lot of interest in our overall pandemic response, including both our vaccine and oral antiviral treatment. We appreciate your feedback.

Pfizer’s purpose - Breakthroughs that change patients’ lives - fuels everything we do and reflects both our passion for science and commitment to patients. We fully understand that we share, along with all other relevant stakeholders, a great responsibility to help ensure equitable access to vaccines and treatments. Distributing these types of products rapidly and at global scale has no precedent in modern public health. As such, close coordination across all stakeholders is critical to the success of our collective efforts.

I know you have requested information on our access strategy for PAXLOVID™, but it is important to first acknowledge that, while PAXLOVID is another tool in the arsenal against COVID-19, vaccinations remain the first line of defense. Since the start of the pandemic, Pfizer and BioNTech’s paramount consideration has been equitable and affordable access to COVID-19 vaccines for all people around the world. In 2021, we delivered on our promise and supplied over 1 billion doses of our vaccine to 99 low- and middle-income countries. This includes more than 400 million doses, or approximately 40% of this supply, that have reached 56 low- and lower-middle-income countries. Thanks to the efforts of all stakeholders, COVAX was able to dramatically increase the rate of vaccine deliveries at the end of 2021. Pfizer and BioNTech have pledged to deliver another billion doses of our COVID-19 vaccine to low- and middle-income countries in 2022.

We believe that to achieve equitable access, one must not only consider the supply of vaccines, but actual vaccinations. There are still considerable challenges governments face when it comes to country readiness and hesitancy, and the public health community has acknowledged that health systems in many countries have been a limiting factor. For example, Pfizer shipped nearly 130 million doses to African countries in 2021, but a number of these governments have requested to delay or pause future shipments due to issues related to country readiness, and we have seen this in other regions as well. Greater investment in readiness efforts in many countries will still be necessary to ensure that vaccines effectively reach populations.

We know that global vaccination targets can be achieved only with support from all global health stakeholders. Pfizer is committed to the task at hand. We are providing our expertise and resources to strengthen healthcare systems where greater support is needed.
Global Access to PAXLOVID

Even before the positive results from our trial, Pfizer sought ways to enable equitable access to address short-, medium- and longer-term needs for this treatment. We continue advancing in our comprehensive plan to provide access to patients all over the world. That said, we have been very open in communicating that, in the early months, supply would be quite constrained.

In anticipation of regulatory authorization or approval globally, Pfizer started manufacturing PAXLOVID at risk in 2021. We now estimate that we will produce up to 120 million courses of treatment by the end of 2022, with 30 million of these treatment courses to be produced in the first half of the year and the remaining 90 million to be produced equally over the final two quarters. The number of steps involved in the complex manufacturing process of PAXLOVID drives a relatively long lead-time of between six and eight months, but we are constantly looking to improve our processes, timelines and expand the supply chain – including scaling up our internal and external network, raw material production and tableting capacity.

Medicines Patent Pool Agreement

Last November, Pfizer and the Medicines Patent Pool (MPP) announced a voluntary license agreement for the COVID-19 oral antiviral treatment. The agreement will enable MPP to facilitate additional production and distribution of this antiviral, pending regulatory authorization or approval.

Under the terms of the agreement, qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply the oral antiviral treatment, in combination with ritonavir, to 95 countries that cover approximately 53% of the world’s population. This includes all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa, as well as countries that have transitioned from lower-middle to upper-middle-income status in the past five years.

Pfizer will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the agreement while COVID-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.

Since the application window for manufacturers closed at the end of last year, MPP and Pfizer have been moving rapidly to review the high volume of applicants, and we expect this process to be finalized next month. Given the tremendous need for this product, we are working with MPP to accelerate timelines wherever possible to try and accelerate the sublicensees’ time to market.

Outreach to Governments and Supranational Organizations

In June 2021, we initiated bilateral outreach, beginning engagement with more than 100 diverse countries in every region as well as supranational organizations like UNICEF. We have also been closely collaborating with the World Health Organization (WHO) and its partners in the Therapeutics pillar of the Access to COVID-19 Tools Accelerator (ACT-A), sharing information about our treatment, approach to pricing, and supply projections. We will share more details with the public on supply agreements with these entities as they become available.

Pricing Approach

Our access strategy aims to deliver safe and effective antiviral therapeutics as soon as possible and at an affordable price. During the pandemic, Pfizer will offer PAXLOVID through a tiered pricing approach based on the income level of each country. High and upper-middle income countries will pay more than lower income countries, which will pay a not-for-profit price.
Pfizer is committed to continuing evolving and improving our response to this pandemic. We welcome the opportunity to engage with other stakeholders in sharing lessons learned and building collaborative solutions to improve healthcare access globally and be one step closer to ending this deadly pandemic.

Warm Regards,

Caroline Roan  
Senior Vice President, Global Health & Social Impact  
Chief Sustainability Officer  
President, The Pfizer Foundation